̽»¨ÊÓƵ

̽»¨ÊÓƵ: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

̽»¨ÊÓƵ initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer

̽»¨ÊÓƵ Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

̽»¨ÊÓƵ Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

̽»¨ÊÓƵ Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data

̽»¨ÊÓƵ Ltd announces expansion of partnership with Seibersdorf Labor GmbH to include manufacture of therapeutic radiopharmaceutical, 225Ac-rhPSMA-10.1

̽»¨ÊÓƵ Announces Clinical Research Collaboration with UCLto Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer

FOR U.S. AUDIENCES ONLY ̽»¨ÊÓƵ Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

FOR U.S. AUDIENCES ONLY ̽»¨ÊÓƵ Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference

FOR US AUDIENCES ONLY ̽»¨ÊÓƵ Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

̽»¨ÊÓƵ Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

̽»¨ÊÓƵ Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA in Treatment of Prostate Cancer

̽»¨ÊÓƵ Highlights Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

̽»¨ÊÓƵ Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-resistant Prostate Cancer (mCRPC)

̽»¨ÊÓƵ Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

̽»¨ÊÓƵ Announces US FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer